Display Settings:

Format

Send to:

Choose Destination

    Diabetes. 2002 Dec;51(12):3582-5.

    Interleukin-1 receptor antagonist genotype is associated with coronary atherosclerosis in patients with type 2 diabetes.

    Marculescu R, Endler G, Schillinger M, Iordanova N, Exner M, Hayden E, Huber K, Wagner O, Mannhalter C.

    Department of Laboratory Medicine, School of Medicine, University of Vienna, Waehringer Guertel 18-20, A-1090 Vienna, Austria.

    Recently, inflammation has received considerable attention in the pathogenesis of both type 2 diabetes and atherosclerosis. The interleukin-1 receptor antagonist (IL-1ra) is a major modulator of the interleukin-1 pro-inflammatory pathway. We studied the relationship between a variable number tandem repeat (VNTR) polymorphism in intron 2 of the IL-1ra gene (IL1RN) and coronary artery disease (CAD) in patients with and without type 2 diabetes, following 787 consecutive patients admitted for suspected CAD. According to the current criteria of the American Diabetes Association, 250 patients had type 2 diabetes. In this group of patients, allele 2 carriers (n = 108) had an increased prevalence of CAD compared with noncarriers (85.2 vs. 73.2%), a difference that remained significant in a multivariate logistic regression model (odds ratio 2.2, 95% CI 1.1-4.3, P = 0.02). No association of CAD with allele 2 carrier status was present among nondiabetic patients (n = 537). Enzyme-linked immunosorbent assays showed decreased baseline plasma levels of IL-1ra in patients with type 2 diabetes, which may in part explain the role of the IL1RN VNTR in these patients.

    PMID: 12453918 [PubMed - indexed for MEDLINE]

    Supplemental Content

    Click here to read

    Patient drug information

    • Anakinra (Kineret®)

      Anakinra is used, alone or in combination with other medications, to reduce the pain and swelling associated with rheumatoid arthritis. Anakinra is in a class of medications called interleukin antagonists. It works by bl...